Prospective Genomics Initiative on Multiple Synchronous Lung Cancer (PGI-MSLC)
NCT ID: NCT03795155
Last Updated: 2020-06-11
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
100 participants
OBSERVATIONAL
2018-12-01
2023-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Prospective Study of Constructing Immune Repertoire to Monitor the Therapeutic Effect in NSCLC Patients
NCT03373955
The Chinese Pulmonary Lymphoepithelioma-like Carcinoma Collaboration Study
NCT06801977
Effects of Different Genetic Mutations on Prognosis in sMPLC Adenocarcinoma Patients
NCT03764371
Clinical Evaluation of Genetron Lung Cancer Panel in Non-small Cell Lung Cancer Patients
NCT05023746
Next-generation Sequencing of Small Cell Lung Cancer to Identify Susceptibility Gene and to Assess Treatment
NCT03244904
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* To define the clonal relationship, genomic landscape and potential driver alterations of MSLC using whole-genome sequencing.
* To determine the intrapatient and intratumor genetic heterogeneity of MSLC.
* To correlate molecular features with clinical parameters and patient outcome.
* To serve as a continuous infrastructure for a large variety of research purposes including: A. Diagnostic research B. Prognostic research C. Biological research D. Interventional trial design testing new therapies in MSLC.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Confirmed diagnosis of multiple synchronous lung cancers (MSLCs) without metastatic disease
* Signed informed consent
Exclusion Criteria
* History of known high-risk infections
* With metastatic tumors except lung
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
RenJi Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Xiaojing Zhao, M.D.
Role: PRINCIPAL_INVESTIGATOR
Ren Ji Hospital
Yujie Fu, Ph.D.
Role: PRINCIPAL_INVESTIGATOR
Ren Ji Hospital
Guanglei Zhuang, Ph.D.
Role: PRINCIPAL_INVESTIGATOR
Ren Ji Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University
Shanghai, Shanghai Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Ma P, Fu Y, Cai MC, Yan Y, Jing Y, Zhang S, Chen M, Wu J, Shen Y, Zhu L, Chen HZ, Gao WQ, Wang M, Gu Z, Bivona TG, Zhao X, Zhuang G. Simultaneous evolutionary expansion and constraint of genomic heterogeneity in multifocal lung cancer. Nat Commun. 2017 Oct 10;8(1):823. doi: 10.1038/s41467-017-00963-0.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RenJiH-2018-056
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.